Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Refobacin Revision-3
- Development stage
- Unknown
- Lead developer
- Zimmer Biomet
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems, Device-based Delivery → Drug Delivery Systems
- Administration
- Orthopedic Implantation (local, Intraoperative)
01
Overview
Refobacin Revision-3 is a **high-viscosity, radiopaque, antibiotic-loaded bone cement specifically formulated for orthopedic revision surgeries**, particularly for hip and knee arthroplasty revisions in infected or high-risk cases. It contains a combination of **gentamicin** and **clindamycin**, each at 1 gram per 40 grams of cement, offering broad antibacterial coverage targeting more than 90% of bacterial pathogens frequently implicated in prosthetic joint infections. Designed for both one- and two-stage revision procedures, it provides prolonged, localized antibiotic release intended to reduce infection risk and re-infection after joint replacements. Developed by Zimmer Biomet, it is intended for use with Zimmer Biomet implants and can also be used in temporary spacers during two-stage revisions[1][3][6].
- Brand names
- Refobacin Revision-3
- Other names
- Refobacin Revision-3 Bone Cement
02
Targets
Bacterial RibosomeBacterial 50S ribosomal subunit
Beyond the preview
Go deeper on Refobacin Revision-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Refobacin Revision-3.